mFOLFOX6方案与奥沙利铂联合替吉奥治疗胃癌肝转移疗效对比

目的 比较mFOLFOX6方案与奥沙利铂联合替吉奥治疗胃癌肝转移患者的疗效及其对患者免疫功能的影响.方法 选择2014年1月-2016年1月收治的134例胃癌肝转移患者作为研究对象,采用随机数字表法分为观察组和对照组,每组67例.观察组患者给予奥沙利铂联合替吉奥进行治疗.对照组患者给予mFOLFOX6方案进行治疗(奥沙利铂+亚叶酸钙+5-氟尿嘧啶),各组均治疗4个疗程.治疗后观察各组患者临床疗效及不良反应发生情况;治疗前及治疗各疗程后评价两组患者卡氏评分;治疗前后分别抽取各组患者静脉血,检测其中CD3+、CD4+、CD8+及CD19+等免疫功能相关指标水平.采用SPSS 22.0软件分析相关数据,计量资料以((x)±s)表示,采用t检验;计数资料以百分数表示,采用x2检验.结果 治疗后,观察组总有效率为52.2％,明显高于对照组的38.8％(P＜0.05);治疗第3疗程及第4疗程后,观察组KPS评分分别为(81.3±9.7)分和(83.2±9.9)分,均明显高于对照组(P＜0.05);治疗后,观察组CD3+、CD4+、CD8+及CD19+含量分别为(54.21±6.38)％、(24.11±2.41)％、(21.33-±3.16)％及(7.18±1.13)％,均明显高于对照组(P＜0.05);观察组各项不良反应发病率均明显低于对照组(P＜0.05).结论 奥沙利铂联合替吉奥治疗胃癌肝转移患者的疗效优于mFOLFOX6方案,对免疫功能的影响小于mFOLFOX6方案,且安全性更佳.

Comparison of efficacy of Oxaliplatin combined with Tegafur Gimeracil Oteracil Potassium Capsule and mFOLFOX6 method in the treatment of gastric cancer with liver metastasis

Objective To compare the efficacy and influence on the immune function of oxaliplatin combined with tegafur gimeracil oteracil potassium capsule and mFOLFOX6 method in the treatment of gastric cancer with liver metastasis.Methods One hundred and thirty-four gastric cancer with liver metastasis patients who underwent treatment from Jan.2014 to Jan.2016 in Yulin First Hospital were selected as the participants and randomly divided observation group (67 cases) and control group (67 cases).The control group was treated by mFOLFOX6 method,while the observation group was treated by oxaliplatin combined with tegafur gimeracil oteracil potassium capsule.After treatment,the curative effects were evaluated.The life quality in each group as performed by KPS method before the treatment and in every period of treatment.Before and after the treatment,the levels of CD3 +,CD4 +,CD8 + and CD19 + were detected in two groups and the toxicity was compared.The SPSS 22.0 software was used to analyze relevant data,the measurement data was described by (x ± s) and using t-test,the enumeration data was described by percentage,using the Chi-square test.Results The total effective rate was 52.2％ in the observation group,higher than the 38.8％ in the control group (P ＜ 0.05).After the third and fourth course of treatment,the karnofsky perfomance status score were (81.3 ± 9.7) and (83.2 ± 9.9),were significantly higher in the observation group than which in the control group (P ＜ 0.05).After the treatment,the levels of CD3 +,CD4+,CD8+ andCD19+ were (54.21 ±6.38)％,(24.11 ±2.41) ％,(21.33±3.16) ％ and (7.18 ±1.13) ％ in the observation group,and higher than the control group (P ＜ 0.05).During the treatment,there were no serious toxicity occurs in the patients and the rates of toxicity were significantly lower in the observation group than which in the control group (P ＜ 0.05).Conclusion Oxaliplatin combined with tegafur gimeracil oteracil potassium capsule has a better effect and safety for therapy in the treatment of gastric cancer with liver metastasis than mFOLFOX6.